PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

dc.contributor.authorNguyen, Bella Hai
dc.contributor.authorMontgomery, Renn
dc.contributor.authorFadia, Mitali
dc.contributor.authorWang, Jiali
dc.contributor.authorAli, Sayed
dc.date.accessioned2020-12-20T20:58:39Z
dc.date.available2020-12-20T20:58:39Z
dc.date.issued2018
dc.date.updated2020-11-23T11:50:49Z
dc.description.abstractAim There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has been studied as a prognostic biomarker in a number of tumors given its central role in antitumoral immune response evasion. Four previously published analyses found PD-L1 positivity to be an adverse survival prognostic factor in MPM. This study aims to further investigate the relationship between PD-L1 expression in mesothelioma tissues and survival outcome. Methods Clinical data of MPM patients from a single institution between 2006 and 2016 were reviewed. Patient's archived tissues were stained with PD-L1 (Clone Ventana SP263). PD-L1 positivity was defined as > 1% membranous staining regardless of intensity. Results Data from fifty eight patients were analyzed. Median age was 73, majority was male (49, 84%) and had ECOG between 0 and 2 (46, 79%). Most common histopathological subtype was epithelioid (42, 72%), 9 (16%) biphasic subtype and 7 (12%) sarcomatoid. Thirty one patients (53%) received best supportive care and twenty seven patients (47%) received chemotherapy or combination treatment. Forty-two patients had positive PD-L1 expression (72.4%). The median survival time for PD-L1 negative group is 15.5 months and 6 months for the positive group. Positive PD-L1 expression is independently correlated with worse prognosis (HR = 2.02; 95% CI, 1.005–4.057; P-value = 0.0484). Conclusions Our analysis found a higher percentage of MPM patients with positive PD-L1 (> 1%) compared to other studies. Highly positive PD-L1 expression was associated with statistically significantly lower median survival time.
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1743-7555
dc.identifier.urihttp://hdl.handle.net/1885/218664
dc.language.isoen_AUen_AU
dc.publisherBlackwell Pub. Asia
dc.sourceAsia-Pacific Journal of Clinical Oncology
dc.titlePD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma
dc.typeJournal article
local.bibliographicCitation.issue1
local.bibliographicCitation.lastpage73
local.bibliographicCitation.startpage69
local.contributor.affiliationNguyen, Bella Hai, The Canberra Hospital
local.contributor.affiliationMontgomery, Renn, College of Health and Medicine, ANU
local.contributor.affiliationFadia, Mitali, College of Health and Medicine, ANU
local.contributor.affiliationWang, Jiali, College of Business and Economics, ANU
local.contributor.affiliationAli, Sayed, College of Health and Medicine, ANU
local.contributor.authoremailrepository.admin@anu.edu.au
local.contributor.authoruidMontgomery, Renn, u4365779
local.contributor.authoruidFadia, Mitali, u5039591
local.contributor.authoruidWang, Jiali, u5298171
local.contributor.authoruidAli, Sayed, u5677745
local.description.notesImported from ARIES
local.identifier.absfor111299 - Oncology and Carcinogenesis not elsewhere classified
local.identifier.ariespublicationu4351680xPUB496
local.identifier.citationvolume14
local.identifier.doi10.1111/ajco.12788
local.identifier.scopusID2-s2.0-85032907687
local.identifier.uidSubmittedByu4351680
local.type.statusPublished Version

Downloads

Back to topicon-arrow-up-solid
 
APRU
IARU
 
edX
Group of Eight Member

Acknowledgement of Country

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.


Contact ANUCopyrightDisclaimerPrivacyFreedom of Information

+61 2 6125 5111 The Australian National University, Canberra

TEQSA Provider ID: PRV12002 (Australian University) CRICOS Provider Code: 00120C ABN: 52 234 063 906